The estimated Net Worth of Capital Management, Llcaldr... is at least $65.7 Milion dollars as of 17 November 2008. Capital Llcaldr owns over 44,887 units of Biospecifics Technologies stock worth over $65,706,612 and over the last 16 years Capital sold BSTC stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Capital Llcaldr BSTC stock SEC Form 4 insiders trading
Capital has made over 3 trades of the Biospecifics Technologies stock since 2008, according to the Form 4 filled with the SEC. Most recently Capital bought 44,887 units of BSTC stock worth $748,715 on 17 November 2008.
The largest trade Capital's ever made was buying 44,887 units of Biospecifics Technologies stock on 17 November 2008 worth over $748,715. On average, Capital trades about 21,994 units every 18 days since 2008. As of 17 November 2008 Capital still owns at least 742,196 units of Biospecifics Technologies stock.
You can see the complete history of Capital Llcaldr stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Biospecifics Technologies
Over the last 33 years, insiders at Biospecifics Technologies have traded over $67,860,045 worth of Biospecifics Technologies stock and bought 7,761,661 units worth $656,708,120 . The most active insiders traders include Capital Management, Llc Kol..., International Plc Endo a Max Link. On average, Biospecifics Technologies executives and independent directors trade stock every 73 days with the average trade being worth of $6,538,649. The most recent stock trade was executed by International Plc Endo on 2 December 2020, trading 7,344,955 units of BSTC stock currently worth $650,028,518.
What does Biospecifics Technologies's logo look like?
Complete history of Capital Llcaldr stock trades at Biospecifics Technologies
Biospecifics Technologies executives and stock owners
Biospecifics Technologies executives and other stock owners filed with the SEC include:
-
Jennifer Chao,
Independent Chairman of the Board -
Michael Schamroth,
Independent Director -
Paul Gitman,
Independent Director -
Mark Wegman,
Director -
Toby Wegman,
Director -
Sarah McCabe,
Stern Investor Relations -
Michael Sherman,
Independent Director -
Corey Fishman,
Independent Director -
Alex Monteith,
Senior Vice President and Chief Business Officer -
Patrick Hutchison,
Chief Financial Officer -
Joseph Truitt,
Chief Executive Officer, Director -
Jeffrey Kenneth Vogel,
-
Jyrki Mattila,
Director -
Thomas Wegman,
President -
Of Edwin H. Wegman Estate,
10% owner -
Patrick M Caldwell,
Principal Financial Officer -
Partners Lp Bio,
10% owner -
Albert Horcher,
-
Lawrence Dobroff,
CFO -
Max Link,
Director -
Henry Morgan,
Director -
George M Gould,
Director -
Matthew Geller,
Director -
Capital Management, Llc Kol...,
-
Capital Management, Llcra C...,
-
Capital Management, Llcaldr...,
-
Capital Management, Llc Kol...,
-
Capital Management, Llcra C...,
-
J Kevin Buchi,
Chief Executive Officer -
International Plc Endo,
10% owner